NCT03359304|Not Yet Recruiting
The Neurofibromatosis-associated Tumor Biobank
Establishment of Neurofibromatosis-associated Tumours Biobank for Future Genomic-based Research Aiming at Improved Outcome Prediction
Loading search results
Establishment of Neurofibromatosis-associated Tumours Biobank for Future Genomic-based Research Aiming at Improved Outcome Prediction
Sponsor study identifier
observational
300
0 countries
N/A
Study Start
March 1, 2018
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
March 1, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
March 1, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Neurofibromatosis-associated Tumor is very rare bone tumor. The investigator set up the biobank to ensure every patient has the chance to participate in future research
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 1, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 25, 2017
Actual (reported)December 2, 2017
Actual (reported)March 1, 2018
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
March 1, 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
March 1, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Detected NF-1 gene expression pattern in neurofibromatosis-asociated tumor
To examine the neurofibromatosis type 1(NF-1) gene expression of the patients with neurofibromatosis-associated tumor
3 years
Asia
Contact the study team to confirm eligibility.
The investigator will collect specimen and blood. If the investigator finds out that the sample doesn't have enough cells to be useful, the investigator may call for an additional sample.
Tingting Ren, phD
Peking University People's Hospital
First Submitted
November 25, 2017
First Posted
December 2, 2017
Study Start
March 1, 2018
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
March 1, 2023
Resiliency Training for Adolescent Neurofibromatosis Patients Via Videoconferencing With Skype
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
March 1, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
December 2, 2017
Record last verified: 2017-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: